SLC46A1 and neoplasm: For tumor-targeted antifolates such as AGF94, which target both FRα and PCFT, FRα or PCFT expression would be sufficient for drug uptake and anti-tumor efficacy (thus compensating for the loss of one system), although expression of both FRα and PCFT would certainly enhance anti-tumor activity.